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Background: There are some reports on the effects of antidepressants on metabolic syndrome. However, our
search in the previously published literature showed a lack of information on the comparison of the effects of
different classes of antidepressants on lipid profile. Therefore, this study was aimed to compare the effects of
fluoxetine and imipramine on serum total cholesterol (TC) and triglyceride (TG) as well as body weight (BW) in
patients with major depressive disorder.
Methods: Fifty one patients, 18 to 70 years of age, with major depressive disorder complied with the criteria of this
preliminary, open-label clinical trial. Subjects received either imipramine (75–200 mg/day) or fluoxetine (20–40 mg/
day) for 8 weeks. Total cholesterol and TG levels, as well as BW were compared at baseline with those at weeks 4
and 8. Data was analyzed by SPSS software version 16.0.
Results: In the fluoxetine group, TC levels decreased from 165.71 mg/dL to 156.71 mg/dL at week 4 (P = 0.07), and to
143.94 mg/dL at week 8 (P = 0.16); TG levels decreased from 129.35 mg/dL to 115.88 mg/dL at week 4 (P <0.001), and
to 110.41 mg/dL at week 8 (P = 0.56). In the imipramine group, TC levels increased from 169.10 mg/dL to 178.69 mg/
dL at week 4 (P = 0.07), and to 208.69 mg/dL at week 8 (P < 0.001) while TG levels increased from 111.73 mg/dL to
128.83 mg/dL at week 4 (P = 0.005), and to 160.90 mg/dL at week 8 (P < 0.001). BW was significantly increased in the
imipramine group at weeks 4 and 8. In the fluoxetine group, BW was non-significantly decreased from 75.69 ± 7.97 Kg
(baseline) to 75.67 ± 8.01 Kg at week 4 (P = 0.88), and to 75.22 ± 8.67 Kg at week 8 (P = 0.20), while in the imipramine
group, BW had significant increases from 72.53 ± 8.55 Kg (baseline) to 73.95 ± 8.61 mg/dL at week 4 (P < 0.001), and to
75.13 ± 8.34 mg/dL at week 8 (P < 0.001).
Repeated measures ANOVA showed significant effects on both TC and TG levels as well as on BW in all patients
receiving imipramine. However, in patients on fluoxetine, repeated measures ANOVA showed significant effects of this
medication only on TC levels in males.
Conclusions: Monitoring TC and TG and BW is recommended before starting imipramine in depressed patients with
increased risk for cardiovascular disease. Fluoxetine may be the preferred agent in those with high or borderline high
lipid levels.
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The lifetime prevalence of depressive disorders has been
reported to be high. National Comorbidity Survey (NCS),
conducted in 1990–1992, noted that the lifetime preva-
lence of major depressive disorder in the United States
was 14.9% for lifetime and 8.6% for 12-month [1]. How-
ever, after the introduction of the DSM-IV criteria, the
National Comorbidity Survey Replication (NCS-R) reported
the prevalence of MDD as 16.2% for lifetime and 6.6% for
12-month by using World Health Organization’s Compos-
ite International Diagnostic Interview (CIDI) [2,3].
Fluoxetine, a specific serotonin reuptake inhibitor (SSRI)
and imipramine, a tricyclic antidepressant (TCA) have been
successfully used in the treatment of major depression for
many years. These drugs differ in their pharmacology, ad-
verse effects, and drug-drug interactions. Fluoxetine is
well absorbed after oral administration and has a large
volume of distribution. It is extensively metabolized in the
liver, and is highly protein bound. Fluoxetine has an elim-
ination half-life (t ½) of 24 to 96 hours; its metabolite t ½,
norfluoxetine, ranges between 168 and 360 hours. There-
fore, this drug should be used with caution in patients
with decreased liver function and metabolic activity [4,5].
On the other hand, imipramine is highly metabolized in
the liver with a t ½ of 6 to 28 hours; its major active me-
tabolite is desipramine. This drug blocks histamine-1 and
alpha-1 receptors and therefore may cause sedation, in-
crease appetite, and orthostatic hypotension. It may also
cause constipation, blurred vision, and urinary retention
due to its anticholinergic effects [5].
Cipriani et al. analyzed data from 102 randomized
clinical trials (RCTs) that compared SSRIs and TCAs,
and noted no overall difference in efficacy between these
two classes of antidepressants. However, SSRIs were
shown to be better tolerated than TCAs according to
the results of this analysis [6].
Since weight changes are among the criteria of depres-
sion and may result in related consequences such as al-
teration in lipid profile, this preliminary study was aimed
to observe and compare the effects of fluoxetine and im-
ipramine (representatives of the two classes of SSRIs and
TCAs) on serum total cholesterol (TC) and triglyceride
(TG), as well as body weight (BW) in depressed patients.
On the other hand, a number of factors such as medi-
cations, appetite, exercise, and medical illnesses may be
of importance regarding weight changes associated with
depression [7].
After searching Medline, and PsychLit from 1970 to
2012, we found that there are a few studies on the effects
of fluoxetine or imipramine on serum TC, TG, and BW in
animals and even fewer reports in depressed patients. For
instance, one study in 1976 reported that prolonged intra-
gastric administration of imipramine in rabbits resulted in
a significant increase in serum cholesterol after 4, 8 and12 weeks [8]. Additionally, association between TCAs and
weight gain as well as association between SSRIs with
abdominal obesity and hypercholesterolemia have been
noted in the literature [9–12].
Activation of sterol regulatory element-binding protein
(SREBP) may be important in understanding metabolic side
effects of psychiatric drugs. Raeder et al. exposed cultured
human glioma cells to some psychotropics. Some antide-
pressants including Imipramine and fluoxetine resulted in
activation of SREBP system. Subsequently, it was noted that
downstream genes that were involved in the biosynthesis of
cholesterol and fatty acid were upregulated by studied anti-
depressants but to a different extent [13].
Based on the knowledge of the authors of the present
study, no previous published study looked at the com-
parison of any SSRIs with TCAs regarding their effects
on TG and TC levels and their relationships with BW in
patients with major depressive disorder. Therefore, this
preliminary study was designed to compare the effects
of short-term use of fluoxetine and imipramine on TC
and TG levels as well as BW in patients who suffered
from major depressive disorder.Methods
Fifty eight patients, 18 to 70 years of age, with major de-
pressive disorder (based on DSM-IV criteria) accepted to
enter this preliminary, open-label, clinical trial. Subjects
received either imipramine or fluoxetine for 8 weeks in
private psychiatric offices in Tehran, Iran. Patients did
not receive any antidepressant or any other medication
(s) that was reported to affect lipid levels or BW (e.g.,
TCAs, antipsychotics, etc.) for 2 weeks before the initi-
ation and during the study. Patients with TC levels above
250 mg/dL (according to the reference of the laboratory
values), and TG levels above 200 mg/dL (according to
the reference of the laboratory values), diabetes mellitus,
a history of any major cardiovascular diseases, and preg-
nant women were excluded from this study. Additionally,
none of the patients should have received electroconvul-
sive therapy within 6 months before the initiation of the
antidepressants. Participants were asked to report any
changes in their diet or appetite during the study. Patients
were assigned to receive oral fluoxetine (20 to 40 mg/d) or
imipramine (75 to 200 mg/d) for 8 weeks. Benzodiaze-
pines were allowed when needed for anxiety, agitation, or
sleep problems. Total cholesterol and TG levels as well as
BW were measured at the initiation time as well as 4 and
8 weeks after starting antidepressants.
Fifty one out of the 58 patients, who signed informed
consent forms, fulfilled the criteria of and participated
in the study. The study was approved by the Ethics
Committee of the Faculty of Pharmacy at Tehran Uni-
versity of Medical Sciences (TUMS) and was conducted
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SPSS software version 16.0 was used to analyze the
data. Independent-sample t-test was performed to com-
pare the means of TC, TG, and BW measures between
the 2 groups at baseline, weeks 4 and 8. Additionally,
paired sample t-test was performed to compare the
means of TC and TG levels, and also BW at weeks 0, 4,
and 8 for each group.
Linear regression was used for each group to find
whether or not the sex or age has any significant effects
on TC or TG levels as well as BW. Repeated measures
ANOVA was used to compare the results of TC and TG
levels as well as BW between weeks 0, 4, and 8 in each
groups. Results are presented as mean ± standard devi-
ation (SD); standard error mean (SEM). Differences were
considered significant when P < 0.05.
Results
Fifty one patients complied with the study criteria and
completed the study. Nineteen patients including 11
males and 8 females (mean age ± SD; SEM = 42.58 ±
15.19; 3.48 years) received fluoxetine while 32 patients
including 13 males and 19 females (mean age ± SD;
SEM = 41.97 ± 14.79; 2.61 years) received imipramine.
The difference in age between the two groups was not
significant (F = 0.017, P = 0.888). Baseline clinical charac-
teristics of patients are shown in Table 1. As shown in
this table, the differences between fluoxetine and imipra-
mine groups at baseline for TC and TG levels as well as
for BW were not statistically significant.
We did not find any reportable changes in patients’
appetite and food intake during the study; this finding
was based on patients’ responses to a set of formatted
questions about hydrocarbate, lipid and protein intake as
well as appetite at every visit.
The results of repeated measure ANOVA and paired
t-test for TC or TG level as well as for BW are shown
in Table 2.
As shown in Table 2, repeated measures ANOVA
showed significant effects on both TC and TG levels as
well as on BW in all patients receiving imipramine and
also in males or females on the same antidepressant.
However, in patients on fluoxetine, repeated measuresTable 1 Baseline clinical characteristics of patients
Imipramine
Age (years); Mean ± SD 41.97 ± 14.79
Age Range (years) 18 – 70
TC (mg/dL) 169.10 ± 36.20
TG (mg/dL) 111.73 ± 36.52
BW (Kg) 72.53 ± 8.55
TC = Total Cholesterol; TG = Triglyceride; BW = Body Weight.ANOVA showed significant effects of this medication
only on TC levels in males.TC levels analysis
Mean TC levels were significantly different between flu-
oxetine and imipramine groups at both week 4 (F = 3.11,
P = 0.04; two-tailed) and week 8 (F = 0.07, P <0.001;
two-tailed).All samples
Paired sample t-test showed that in the fluoxetine group,
TC level had a trend toward the significant decrease from
165.71 ± 35.80 mg/dL (baseline) to 156.71 ± 35.53 mg/dL
at week 4 (P = 0.07), and a non-significant decrease to
143.94 ± 44.71 mg/dL at week 8 (P = 0.16). On the other
hand, in the imipramine group, TC level had a trend to-
ward the significant increase from 169.10 ± 36.20 mg/dL
(baseline) to 178.69 ± 42.78 mg/dL at week 4 (P = 0.07),
and a significant increase to 208.69 ± 43.33 mg/dL at week
8 (P < 0.001).Male sample
Paired sample t-test showed that in the fluoxetine group,
TC level had a non-significant decrease from 154.60 ±
29.39 mg/dL (baseline) to 147.80 ± 27.93 mg/dL at week 4
(P = 0.39), and a significant decrease to 128.70 ± 34.96 mg/
dL at week 8 (P = 0.006). On the other hand, in the imipra-
mine group, TC level had a non-significant increase from
159.92 ± 33.18 mg/dL (baseline) to 171.46 ± 39.49 mg/dL
at week 4 (P = 0.21), and a significant increase to 194.38 ±
40.42 mg/dL at week 8 (P < 0.001).Female samples
Paired sample t-test showed that in the fluoxetine group,
TC level had a significant decrease from 181.57 ±
40.29 mg/dL (baseline) to 169.43 ± 43.30 mg/dL at week
4 (P = 0.036), and a non-significant decrease to 165.71 ±
50.58 mg/dL at week 8 (P = 0.86). On the other hand, in
the imipramine group, TC level had a non-significant in-
crease from 176.56 ± 37.85 mg/dL (baseline) to 184.56 ±
45.68 mg/dL at week 4 (P = 0.22), and a significant in-
crease to 220.31 ± 43.31 mg/dL at week 8 (P = 0.003).Fluoxetine Statistics
42.58 ± 15.19 F = 0.017, P = 0.888
18 - 68
165.71 ± 35.80 F = 0.088, P = 0.715
129.35 ± 26.61 F = 0.088, P = 0.715
75.69 ± 7.97 F = 0.059, P = 0.114
Table 2 Effects of Imipramine and Fluoxetine on serum TC and TG levels, and BW
Groups Paired t-test; Within groups changes
between weeks 0 and 4 (p value)
Paired t-test; Within groups changes
between weeks 4 and 8 (p value)
Repeated measures ANOVA;
F (p value)
TC level (mg/dL)
Imipramine
√ All subjects 9.59 (0.07**) 30.00 (<0.001*) 24.68 (<0.001*)
o Male 11.54 (0.21) 22.92 (<0.001*) 11.07 (<0.001*)
o Female 8.00 (0.22) 35.75 (0.003*) 13.88 (<0.001*)
Fluoxetine
√ All subjects 9.00 (0.07**) 12.77 (0.16) 2.93 (0.07**)
o Male 6.80 (0.39) 19.10 (0.006*) 6.67 (0.027*)
o Female 12.14 (0.04*) 3.72 (0.86) 0.22 (0.810)
TG level (mg/dL)
Imipramine
√ All subjects 17.10 (0.005*) 32.07 (<0.001*) 18.88 (<0.001*)
o Male 11.75 (0.013*) 26.75 (<0.001*) 24.06 (<0.001*)
o Female 20.66 (0.036*) 35.62 (0.007*) 9.53 (0.001*)
Fluoxetine
√ All subjects 13.47 (<0.001*) 5.47 (0.56) 2.59 (0.09)
o Male 14.27 (0.016*) 9.36 (0.30) 3.24 (0.06**)
o Female 12.00 (<0.001*) 1.67 (0.94) 0.26 (0.78)
BW (Kg)
Imipramine
√ All subjects 1.42 (<0.001*) 1.18 (<0.001*) 29.70 (<0.001*)
o Male 1.07 (0.009*) 1.00 (0.007*) 11.56 (<0.001*)
o Female 1.66 (<0.001*) 1.31 (0.008*) 18.54 (0.001*)
Fluoxetine
√ All subjects 0.02 (0.88) 0.45 (0.20) 1.51 (0.24)
o Male 0.18 (0.44) 0.05 (0.85) 0.41 (0.54)
o Female 0.36 (0.25) 1.21 (0.14) 4.06 (0.05**)
* Statistically significant effect ** Trend towards significant effect.
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were not dependent on age when analyzing the data for
all subjects.
TG levels analysis
Mean TG levels were not significantly different between
fluoxetine and imipramine groups at week 4 (F = 1.88,
P = 0.20; two-tailed) but were significant at week 8 (F =
1.33, P = 0.002; two-tailed).
All samples
Paired sample t-test showed that in the fluoxetine
group, TG level had a significant decrease from
129.35 ± 26.61 mg/dL (baseline) to 115.88 ± 26.87 mg/
dL at week 4 (P < 0.001), and a non-significant decrease
to 110.41 ± 48.30 mg/dL at week 8 (P = 0.56). On the
other hand, in the imipramine group, TG level had sig-
nificant increases from 111.73 ± 36.52 mg/dL (baseline)to 128.83 ± 35.27 mg/dL at week 4 (P = 0.005), and to
160.90 ± 56.04 mg/dL at week 8 (P < 0.001).
Male samples
Paired sample t-test showed that in the fluoxetine
group, TG level had a significant decrease from 130.45
± 32.92 mg/dL (baseline) to 116.18 ± 33.20 mg/dL at
week 4 (P = 0.016), and a non-significant decrease to
106.82 ± 50.84 mg/dL at week 8 (P = 0.30). On the other
hand, in the imipramine group, TG level had significant
increases from 115.42 ± 37.55 mg/dL (baseline) to
127.17 ± 40.54 mg/dL at week 4 (P = 0.013), and to
153.92 ± 42.94 mg/dL at week 8 (P < 0.001).
Female samples
Paired sample t-test showed that in the fluoxetine group,
TG level had a significant decrease from 127.33 ±
9.52 mg/dL (baseline) to 115.33 ± 10.25 mg/dL at week 4
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46.98 mg/dL at week 8 (P = 0.94). On the other hand, in
the imipramine group, TG level had significant increases
from 109.28 ± 36.69 mg/dL (baseline) to 129.94 ± 32.50 mg/
dL at week 4 (P = 0.036), and to 165.56 ± 64.08 mg/dL at
week 8 (P = 0.007). The changes in TG levels were
not dependent on age when analyzing the data for all
samples.
Body weight analysis
Mean BW were not significantly different between fluox-
etine and imipramine groups at week 4 (F = 0.05, P = 0.41;
two-tailed) and week 8 (F = 0.02, P = 0.87; two-tailed).
All samples
Paired sample t-test showed that in the fluoxetine group,
BW was non-significantly decreased from 75.69 ± 7.97
Kg (baseline) to 75.67 ± 8.01 Kg at week 4 (P = 0.88), and
to 75.22 ± 8.67 Kg at week 8 (P = 0.20). On the other
hand, in the imipramine group, BW had significant
increases from 72.53 ± 8.55 Kg (baseline) to 73.95 ±
8.61 mg/dL at week 4 (P < 0.001), and to 75.13 ±
8.34 mg/dL at week 8 (P < 0.001).
Male samples
Paired sample t-test showed that in the fluoxetine group,
BW had non-significant increases from 78.68 ± 7.71 Kg
(baseline) to 78.86 ± 7.53 Kg at week 4 (P = 0.44), and to
78.91 ± 7.62 Kg at week 8 (P = 0.85). On the other hand,
in the imipramine group, BW had significant increases
from 76.85 ± 8.08 Kg (baseline) to 77.92 ± 7.88 Kg at
week 4 (P = 0.009), and to 78.92 ± 7.61 Kg at week 8
(P = 0.007).
Female samples
Paired sample t-test showed that in the fluoxetine group,
BW had non-significant decreases from 71.00 ± 6.24 Kg
(baseline) to 70.64 ± 6.24 Kg at week 4 (P = 0.25), and to
69.43 ± 7.21 Kg at week 8 (P = 0.14). On the other hand,
in the imipramine group, BW had significant increases
from 69.58 ± 7.73 Kg (baseline) to 71.24 ± 8.20 mg/dL at
week 4 (P < 0.001), and to 72.53 ± 7.97 mg/dL at week 8
(P = 0.008).
It should be mentioned that the changes in BW mea-
sures were not dependent on age when analyzing the
data for all patients. Using regression analysis did not
detect any association between BW (independent vari-
able) and either TC or TG levels (dependent variables)
in weeks 0, 4, and 8; no significant association was found
between these parameters.
Discussion
Even though there are some literature on the effects of
antidepressants on lipid factors and BW, our study wasdesigned to compare the effects of fluoxetine with im-
ipramine on these factors simultaneously.
In a letters to the editor, Roessner and colleagues
reported a case in which TC level was increased in a
woman with severe recurrent depression who was taking
doxepin [14]. In another study in 1994 by Pollack et al.,
consumption of nortriptyline after 7 months showed sig-
nificant elevation in TG and very-low-density lipopro-
teins (VLDL) levels in 26 elderly patients suffering
depression [15].
A case of a hypercholesterolemic female, with post-
partum depression, who started receiving fluoxetine two
weeks after her labour, was previously reported. The
woman’s TC and TG levels was measured prior to as
well as 4 and 8 weeks after the initiation of the fluoxet-
ine. Serum TC level was decreased from 242 mg/dL at
the baseline to 224 mg/dl after 4 weeks and to 202 mg/
dl after 8 weeks [16]. Similarly, triglyceride level was
decreased from 516 mg/dL at week 0 to 448 mg/dL at
week 4 and further to 404 mg/dL at week 8 [16]. Even
though this patient was started on fluoxetine after
labour, it should be noted that a part of the change in
TC and TG levels may have been due to the nature of
pregnancy and the related physiological changes during
and after this time.
In a study by Raeder et al. on patients on SSRIs who
were based on a cross-sectional survey in Hordaland
county in Norway (The Hordaland Health Study ‘97-’99),
it was noted that use of most SSRIs may be associated
with some metabolic changes. This study reported that
sertraline, fluoxetine, or fluvoxamine, in 131 patients,
was associated with both abdominal obesity and hyper-
cholesterolemia. However, in 187 patients on paroxetine,
the use of the drug showed association with obesity but
not with hypercholesterolemia. Additionally, it was noted
that there was no association between the use of citalo-
pram in 142 patients with any metabolic factor or lipid
profile [12].
On the other hand, association between TCAs (e.g. im-
ipramine) and weight gain has been reported in the litera-
ture. Fernstrom et al. examined weight gain in patients
taking imipramine 200–250 mg per day for 16 weeks and
noted statistically significant increases in weight and body
mass index of the patients [17].
Frank et al. reported weight changes in patients with
recurrent major depression who were receiving about
215 mg of imipramine per day for over 5 months [18].
This study noted non-significant, minimal changes in
body weight during the first 9 weeks of the treatment.
On the other hand, different results regarding weight
gain have been reported with different agents in SSRI
family. Several studies have reported weight loss with
short-term use of fluoxetine [19,20]. The literature was
reviewed regarding the relative risk for antidepressant-
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that TCAs may cause more weight gain than SSRIs. It
also noted that long-term use of paroxetine increases
weight more than the use of other SSRIs.
Interestingly, a study by Sep-Kowalikowa and collea-
gues, in 1992, on 329 depressed and neurotic patients
noted increases in weight of patients receiving amitrip-
tyline or doxepin but reduction in this factor in those re-
ceiving imipramine [22].
Fava et al. evaluated weight changes in patients on 26
to 32 weeks treatment with, paroxetine, sertraline, or
fluoxetine. This long-term study noted that paroxetine
resulted in significant weight increase, however, sertra-
line increased and fluoxetine decreased BW in non-
significant manners [23].
To our knowledge, no previous study compared the
alterations in TC and TG levels as well as BW in
patients on imipramine with those on fluoxetine at the
same time. The present study compared the effects of
short-term use of fluoxetine and imipramine on the
above factors in patients with major depressive disorder.
Our study noted a trend toward a significant decrease
in TC serum levels of patients on fluoxetine after 4 weeks
and a non-significant decrease at the eighth week. Im-
ipramine showed a trend toward a significant increase in
TC levels after 4 weeks and a significant increase in this
parameter at the eighth week. In addition, our study
noted a significant decrease in TG serum levels of
patients on fluoxetine after 4 weeks and a non-
significant decrease at the eighth week. On the other
hand, Imipramine showed significant increases in TG
levels at weeks 4 and 8. The changes in TC and TG
levels in both groups were in the normal range and did
not seem to be clinically significant. However, these
changes can become clinically important in patients with
high or low normal TC and TG levels or in those with
risk factors for developing hypercholesterolemia. There
are a few studies that have evaluated the effects of SSRIs
or TCAs on lipid profile. TCAs have been noted to have
unfavourable effects on TG and low-density lipoprotein
cholesterol, probably, because of the weight gain asso-
ciated with TCAs [24]. Raeder et al. reported that SSRIs
as a group were associated with hypercholesrterolemia
[12]. However, our study showed the opposite effects for
fluoxetine.
It should also be noted that the duration of this study
may not have been long enough to show the chronic
effects of the studied antidepressants on lipid profile.
There were some other limitations in our study that
could have affected the results. Originally, we planned to
perform a randomized, double-blind trial. Due to the
fact that imipramine was available in tablet form and flu-
oxetine in capsule form, we were not able to get these
medications in the same form at the time. However,since our study primarily was looking into the effects of
the drugs on serum TC and TG levels that are not con-
sidered as subjective values, we did not think an open-
label study would significantly interfere with the results.
Another reason was that when we initiated the study,
many psychiatrists in Iran preferred TCAs over SSRIs
for the treatment of major depression. For this reason,
the number of patients on imipramine was much more
than those on fluoxetine.
Conclusions
Clinicians should consider medical conditions of patients
and the changes in weight, TC and TG levels of patients,
especially those with cardiovascular risk, and any drug-drug
interaction before initiating fluoxetine or imipramine. Flu-
oxetine may be suggested to be used in depressed patients
with high normal TC or in individuals with a high risk to
develop hypercholesterolemia. Further studies are needed
to evaluate the effects of long-term use of imipramine and
fluoxetine on lipid profile and BW in depressed patients.
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